These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 14600530)

  • 1. Acute tubular necrosis in a patient receiving tenofovir.
    Lee JC; Marosok RD
    AIDS; 2003 Nov; 17(17):2543-4. PubMed ID: 14600530
    [No Abstract]   [Full Text] [Related]  

  • 2. Tenofovir-related nephrotoxicity in HIV-infected patients.
    Barrios A; García-Benayas T; González-Lahoz J; Soriano V
    AIDS; 2004 Apr; 18(6):960-3. PubMed ID: 15060449
    [No Abstract]   [Full Text] [Related]  

  • 3. Renal lesions in HIV-1-positive patient treated with tenofovir.
    Créput C; Gonzalez-Canali G; Hill G; Piketty C; Kazatchkine M; Nochy D
    AIDS; 2003 Apr; 17(6):935-7. PubMed ID: 12660548
    [No Abstract]   [Full Text] [Related]  

  • 4. Proximal tubular kidney damage and tenofovir: a role for mitochondrial toxicity?
    Saumoy M; Vidal F; Peraire J; Sauleda S; Vea AM; Viladés C; Ribera E; Richart C
    AIDS; 2004 Aug; 18(12):1741-2. PubMed ID: 15280790
    [No Abstract]   [Full Text] [Related]  

  • 5. Acute renal failure associated with tenofovir treatment in a patient with acquired immunodeficiency syndrome.
    Schaaf B; Aries SP; Kramme E; Steinhoff J; Dalhoff K
    Clin Infect Dis; 2003 Aug; 37(3):e41-3. PubMed ID: 12884188
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fanconi-like syndrome and rhabdomyolysis in a person with HIV infection on highly active antiretroviral treatment including tenofovir.
    Callens S; De Roo A; Colebunders R
    J Infect; 2003 Oct; 47(3):262-3. PubMed ID: 12963392
    [No Abstract]   [Full Text] [Related]  

  • 7. Pancreatitis in an HIV-infected person on a tenofovir, didanosine and stavudine containing highly active antiretroviral treatment.
    Callens S; De Schacht C; Huyst V; Colebunders R
    J Infect; 2003 Aug; 47(2):188-9. PubMed ID: 12860159
    [No Abstract]   [Full Text] [Related]  

  • 8. Tenofovir nephrotoxicity: acute tubular necrosis with distinctive clinical, pathological, and mitochondrial abnormalities.
    Herlitz LC; Mohan S; Stokes MB; Radhakrishnan J; D'Agati VD; Markowitz GS
    Kidney Int; 2010 Dec; 78(11):1171-7. PubMed ID: 20811330
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Lipid profile and body fat--significant "side effect" of antiretroviral therapy. Tenofovir: favorable profile of adverse effects].
    MMW Fortschr Med; 2003 Apr; 145 Spec No 1():83. PubMed ID: 15011603
    [No Abstract]   [Full Text] [Related]  

  • 10. Marked elevation of the creatine phosphokinase level in a patient receiving tenofovir.
    Shere-Wolfe KD; Verley JR
    Clin Infect Dis; 2002 Nov; 35(9):1137. PubMed ID: 12384851
    [No Abstract]   [Full Text] [Related]  

  • 11. ASN clinical pathological conference. Tenofovir-related ATN (severe).
    Atta MG; Stokes MB
    Clin J Am Soc Nephrol; 2013 May; 8(5):882-90. PubMed ID: 23371959
    [No Abstract]   [Full Text] [Related]  

  • 12. Tenofovir disoproxil fumarate.
    Kumar A
    Drugs; 2003; 63(15):1609-10. PubMed ID: 12887267
    [No Abstract]   [Full Text] [Related]  

  • 13. EU issues warning about HAART regimen.
    AIDS Patient Care STDS; 2004 Jan; 18(1):56-7. PubMed ID: 15080094
    [No Abstract]   [Full Text] [Related]  

  • 14. Warning issued on non-response rates.
    AIDS Patient Care STDS; 2003 Oct; 17(10):539. PubMed ID: 14588094
    [No Abstract]   [Full Text] [Related]  

  • 15. Tenofovir disoproxil fumarate.
    Antoniou T
    Drugs; 2003; 63(15):1609-10. PubMed ID: 12887266
    [No Abstract]   [Full Text] [Related]  

  • 16. Evolution of lipid abnormalities in patients switched from stavudine- to tenofovir-containing regimens.
    Lafeuillade A; Jolly P; Chadapaud S; Hittinger G; Lambry V; Philip G
    J Acquir Immune Defic Syndr; 2003 Aug; 33(4):544-6. PubMed ID: 12869846
    [No Abstract]   [Full Text] [Related]  

  • 17. Fanconi syndrome and acute renal failure in a patient treated with tenofovir: a call for caution.
    Gaspar G; Monereo A; García-Reyne A; de Guzmán M
    AIDS; 2004 Jan; 18(2):351-2. PubMed ID: 15075563
    [No Abstract]   [Full Text] [Related]  

  • 18. Tenofovir-induced kidney disease: an acquired renal tubular mitochondriopathy.
    Perazella MA
    Kidney Int; 2010 Dec; 78(11):1060-3. PubMed ID: 21076445
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Does tenofovir increase efavirenz hepatotoxicity?
    Lattuada E; Lanzafame M; Carolo G; Gottardi M; Concia E; Vento S
    AIDS; 2008 May; 22(8):995. PubMed ID: 18453862
    [No Abstract]   [Full Text] [Related]  

  • 20. Renal safety of tenofovir in HIV treatment-experienced patients.
    Izzedine H; Isnard-Bagnis C; Hulot JS; Vittecoq D; Cheng A; Jais CK; Launay-Vacher V; Deray G
    AIDS; 2004 Apr; 18(7):1074-6. PubMed ID: 15096814
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.